BioCentury
ARTICLE | Clinical News

Canakinumab reduces lung cancer mortality, headed for Phase III

September 1, 2017 7:55 PM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) said canakinumab (ACZ885) significantly reduced lung cancer incidence and associated mortality vs. placebo in the Phase III CANTOS cardiovascular outcomes trial in patients with a prior heart attack and inflammatory atherosclerosis. Spokesperson Eric Althoff told BioCentury that Novartis plans to start Phase III trials of the mAb against IL-1 beta to treat lung cancer in 1Q18.

Data from the additional pre-planned analysis of CANTOS were presented at the European Society of Cardiology meeting in Barcelona and published in The Lancet and the New England Journal of Medicine. The double-blind, international CANTOS trial tested quarterly doses of 50, 150 and 300 mg subcutaneous canakinumab in 10,061 patients with a high-sensitivity C-reactive protein (hsCRP) level of ≥2 mg/L and a myocardial infarction (MI) at ≥1 month prior to study entry...

BCIQ Target Profiles

Interleukin-1 (IL-1) beta